Etanercept
- Generic Name
- Etanercept
- Brand Names
- Enbrel, Eticovo, Benepali, Erelzi, Nepexto
- Drug Type
- Biotech
- CAS Number
- 185243-69-0
- Unique Ingredient Identifier
- OP401G7OJC
- Background
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).
- Indication
Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is also used to manage the symptoms of psoriatic arthritis and ankylosing spondylitis.
- Associated Conditions
- Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
- Conditions
- ReductionPsoriatic ArthritisWithdrawal
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 270
- Registration Number
- NCT04610476
- Locations
- 🇩🇪
Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany
Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis
- Conditions
- Juvenile Idiopathic ArthritisObesityRheumatoid Arthritis
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Duke University
- Target Recruit Count
- 30
- Registration Number
- NCT04585711
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis
- Conditions
- Psoriatic ArthritisAnkylosing SpondylitisRheumatoid Arthritis
- Interventions
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- AryoGen Pharmed Co.
- Target Recruit Count
- 583
- Registration Number
- NCT04582084
- Locations
- 🇮🇷
Alzahra Hospital, Isfahan, Iran, Islamic Republic of
🇮🇷Connective Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, East Azerbaijan, Iran, Islamic Republic of
🇮🇷Hafez Hospital, Shiraz, Fars, Iran, Islamic Republic of
Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Device: Sofusa DoseConnect
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04559412
- Locations
- 🇺🇸
Atlanta Research Center for Rheumatology, Atlanta, Georgia, United States
Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 763
- Registration Number
- NCT04507763
- Locations
- 🇮🇶
Pfizer, Baghdad, Iraq
Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 763
- Registration Number
- NCT04507776
- Locations
- 🇮🇶
Pfizer, Baghdad, Iraq
Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1493
- Registration Number
- NCT04428424
- Locations
- 🇮🇶
Pfizer, Baghdad, Iraq
Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 486
- Registration Number
- NCT04428411
- Locations
- 🇮🇶
Pfizer, Baghdad, Iraq
Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 127
- Registration Number
- NCT04428502
- Locations
- 🇮🇶
Pfizer, Baghdad, Iraq
Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 486
- Registration Number
- NCT04398732
- Locations
- 🇮🇶
Pfizer, Baghdad, Iraq
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.